Browser storage is unavailable. Keep this page open and export your collection before leaving.
BioStack is building the data engine for healthcare and drug discovery AI. The bottleneck is not models. It is access to high-quality biological data. Clinical and experimental data is fragmented, unstructured, and locked inside hospitals, labs, and CROs, while generating new data is slow and expensive. BioStack fixes this with proprietary clinical
BioStack is building the data engine for healthcare and drug discovery AI. The bottleneck is not models. It is access to high-quality biological data. Clinical and experimental data is fragmented, unstructured, and locked inside hospitals, labs, and CROs, while generating new data is slow and expensive. BioStack fixes this with proprietary clinical and preclinical data pipelines that turn real biomedical workflows into ML-ready training environments.
We structure longitudinal multimodal data across imaging, EHR, and experimental assays, then package it for post-training and reinforcement learning so models can learn how research and care actually happen. Instead of static datasets, BioStack gives AI labs workflow-aligned data and environments that improve reasoning, decision-making, and real-world performance in biology and medicine.
I'm the co-founder and CEO of BioStack Platforms. In another life, I was a cancer genomics researcher at Stanford, Yale, Carnegie Mellon, and the Max-Planck Institute. I also worked as an early researcher with top AI labs on RL tasks and benchmarks across healthcare and biotech. Hailing from Mumbai, I attended IISER Mohali and Carnegie Mellon for my BS and MS degrees respectively.
I am the Co-founder and CTO at BioStack Platforms. Prior to this, I was a Gen AI scientist at AWS. Before that, I was a researcher at MIT. I have published 40+ papers with 1800+ citations across top venues like CVPR, neurIPS, EMNLP etc. in ML, GenAI, NLP. I completed my MS from UCLA.
Founded 2025 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
Anthrogen is engineering post-modality biology. Today's modalities reflect historical contingencies in biological progress, not fundamental categories. We develop the AI systems that design modular biological machines and the…
Founders · Product
Same product type · Infrastructure
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving…
Founders · Product
Same product type · Infrastructure
Transform scattered lab data into structured insights. Labric automatically captures instrument data, enables AI-powered analysis, and saves research teams hundreds of hours.
Founders · Product · How it works
Same product type · Infrastructure
What if we made as many cancer drugs next year as we have in the last decade?
Founders · Product
Same product type · Infrastructure
Spatial proteomics from H&E and multimodal patient data imputation. Lattice predicts spatially resolved protein-marker maps from routine H&E slides as virtual multiplex immunofluorescence (mIF) channels, transforming incomplete patient…
Founders · Product · How it works
Same product type · Infrastructure
Compute free energy differences, binding conformations & hydration sites, with ab initio accuracy, orders of magnitude faster than traditional simulations.
Founders · Product
Same product type · Infrastructure
